Milestone Pharmaceuticals Inc. (MIST)

1.6900 +0.0300 (+1.81%) At close: 04:00PM EDT

Milestone Pharmaceuticals Inc.

1111 Dr. Frederik-Philips Boulevard
Suite 420
Montreal, QC H4M 2X6
Canada
514 336 0444
https://www.milestonepharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 47

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Joseph G. Oliveto M.B.A.	CEO, President & Director	949.47k	N/A	1968
Mr. Amit Hasija	CFO & Executive VP of Corporate Development	634.89k	N/A	1973
Dr. David B. Bharucha FACC, M.D., Ph.D.	Chief Medical Officer	691.43k	N/A	1962
Dr. Philippe Douville M.B.A., Ph.D.	Founder, Strategic Advisor & Member of Scientific Advisory Board	N/A	N/A	1962
Mr. Jeffrey Nelson	Chief Operating Officer	N/A	N/A	1981
Ms. Kim Fox	Vice President of Communications	N/A	N/A	N/A
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.	Chief Medical Advisor & Member of the Scientific Advisory Board	N/A	N/A	1956
Dr. Guy Rousseau	SVP of Regulatory Affairs and Quality Management	N/A	N/A	N/A
Ms. Anita Holz	VP & Head of Medical Affairs	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Corporate Governance

Milestone Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.